Press ReleasesNHS Reimburses The Cost Of Cannabis Treatment To The...

NHS Reimburses The Cost Of Cannabis Treatment To The First Zerenia Clinics UK Patient



KHIRON Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), continues to spearhead the medical cannabis market in the United Kingdom by successfully attaining, for the first time, full reimbursement by the NHS of costs associated to cannabis-based medication and clinic fees for a patient enrolled in Zerenia™ Clinics UK. The patient was referred to the team at Zerenia™ Clinics UK for assistance with evaluation and advice on cannabis-based treatment options.

This ground-breaking step validates Khiron’s scientific and data-driven approach to demonstrate the efficacy, safety and cost-effectiveness of CBMPs on the management of chronic conditions such as pain and anxiety. The Company, who continues to train doctors on the prescription of CBMPs, will be presenting its real-world evidence (RWE) at the upcoming International Congress on Clinical Trials on Cannabis to an international audience of medical doctors in London’s Canary Wharf on mid-February.

Franziska Katterbach, President of Khiron Europe, comments: “There is huge demand for medicinal cannabis in the UK. More than 1.4 million British self-medicate illegally with cannabis, half of whom medicate every day, with a total spend on illicit cannabis is an estimated £2.6 billion every year.

“On top of that, the estimated wait times for NHS specialist consultations range drastically, but in certain areas can be up to nine months. We are prepared to work with the NHS and provide our outstanding clinical resources, medical cannabis products and certified training tools to decrease wait times for patients and ensure access to life changing medication.

“Having a route for patient reimbursement for cannabis-based medicinal products is an important pillar of our global strategy which we just finally achieved with mandatory reimbursement in Colombia.”

Latest news

Treasury Should “Unlock” Cannabis Economic Benefits, Says CIC

PRESS RELEASE THE Treasury has been urged to ”unlock the very significant economic potential” of the medical cannabis, hemp, and...

Bloomwell Group Closes Multi-Million Euro Growth Capital Round With Leading US Venture Capital Investors, And Award-Winning Actor, Moritz Bleibtreu

PRESS RELEASE FRANKFURT-based medical cannabis holding company Bloomwell Group (“Bloomwell,” “Bloomwell Group,” or the “Company”) has closed a significant multi-million Euro funding...

Norway Hosts First Public Meeting On Medical Cannabis Amid ‘Early First Steps’ Towards Potential Reform

NORWAY, one of the most cautious states in Europe when it comes to cannabis liberalisation, recently held a public...

Cutbill Jacoby PR Launches To Focus On Emerging Industries

PRESS RELEASE Cutbill Jacoby, a London-based Communications and PR agency for emerging industries, launches to initially service the fast-growing industrial...

Sana Healthcare Becomes Script Assist: Company Rebrands To Focus On Innovative Problem-Solving Platform

SANA Healthcare will from today be known as Script Assist after the company’s innovative platform which provides clinicians with...

Love Hemp ‘Rigorously Refutes’ Allegations Of Fraud Levelled By Former Managing Director

LOVE Hemp has responded to damning allegations made publicly by its former managing director Philip Small, who left the...

Must read

Love Hemp ‘Rigorously Refutes’ Allegations Of Fraud Levelled By Former Managing Director

LOVE Hemp has responded to damning allegations made publicly...

You might also likeRELATED
Recommended to you